Selected article for: "monophosphate form and template strand"
Author: Yin, Wanchao; Luan, Xiaodong; Li, Zhihai; Xie, Yuanchao; Zhou, Ziwei; Liu, Jia; Gao, Minqi; Wang, Xiaoxi; Zhou, Fulai; Wang, Qingxia; Wang, Qingxing; Shen, Dandan; Zhang, Yan; Tian, Guanghui; Aisa, Haji A.; Hu, Tianwen; Wei, Daibao; Jiang, Yi; Xiao, Gengfu; Jiang, Hualiang; Zhang, Leike; Yu, Xuekui; Shen, Jingshan; Zhang, Shuyang; Xu, H. Eric
Title: Structural basis for repurpose and design of nucleoside drugs for treating COVID-19
  • Cord-id: o2iny77o
  • Document date: 2020_11_2
    • ID: o2iny77o
    Snippet: SARS-CoV-2 has caused a global pandemic of COVID-19 that urgently needs an effective treatment. Nucleoside analog drugs including favipiravir have been repurposed for COVID-19 despite of unclear mechanism of their inhibition of the viral RNA polymerase (RdRp). Here we report the cryo-EM structures of the viral RdRp in complex with favipiravir and two other nucleoside inhibitor drugs ribavirin and penciclovir. Ribavirin and the ribosylated form of favipiravir share a similar ribose scaffold that
    Document: SARS-CoV-2 has caused a global pandemic of COVID-19 that urgently needs an effective treatment. Nucleoside analog drugs including favipiravir have been repurposed for COVID-19 despite of unclear mechanism of their inhibition of the viral RNA polymerase (RdRp). Here we report the cryo-EM structures of the viral RdRp in complex with favipiravir and two other nucleoside inhibitor drugs ribavirin and penciclovir. Ribavirin and the ribosylated form of favipiravir share a similar ribose scaffold that is distinct from penciclovir. However, the structures reveal that all three inhibitors are covalently linked to the primer strand in a monophosphate form despite the different chemical scaffolds between favipiravir and penciclovir. Surprisingly, the base moieties of these inhibitors can form mismatched pairs with the template strand. Moreover, in view of the clinical disadvantages of remdesivir mainly associated with its prodrug form, we designed several orally-available remdesivir parent nucleoside derivatives, including VV16 that showed 5-fold more potent than remdesivir in inhibition of viral replication. Together, these results demonstrate an unexpected promiscuity of the viral RNA polymerase and provide a basis for repurpose and design of nucleotide analog drugs for COVID-19. One Sentence Summary Cryo-EM structures of the RNA polymerase of SARS-CoV-2 reveals the basis for repurposing of old nucleotide drugs to treat COVID-19.

    Search related documents:
    Co phrase search for related documents
    • active site and additional nucleotide: 1, 2
    • active site and adenosine analog: 1, 2, 3
    • active site and low temperature: 1
    • active triphosphate form and acute respiratory syndrome: 1, 2, 3, 4, 5
    • active triphosphate form and additional nucleotide: 1
    • active triphosphate form and lung tissue: 1
    • acute respiratory syndrome and additional nucleotide: 1
    • acute respiratory syndrome and adenosine analog: 1, 2, 3, 4, 5
    • acute respiratory syndrome and low temperature: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung tissue negative: 1, 2, 3, 4
    • adenosine analog and lung function: 1
    • low temperature and lung function: 1